PRIOR AUTHORIZATION CRITERIA

<table>
<thead>
<tr>
<th>BRAND NAME</th>
<th>EMEND</th>
</tr>
</thead>
<tbody>
<tr>
<td>(generic)</td>
<td>(aprepitant capsules) (aprepitant oral suspension) (fosaprepitant dimeglumine injection)</td>
</tr>
</tbody>
</table>

Status: CVS Caremark Criteria
Type: Post Limit Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Emend (aprepitant) capsules and oral suspension
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Emend for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of:
• acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
• nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Emend capsules, in combination with other antiemetic agents, are indicated in patients 12 years of age and older for the prevention of:
• acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
• nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Prevention of Postoperative Nausea and Vomiting (PONV)
Emend capsules are indicated in adults for the prevention of postoperative nausea and vomiting.

Limitations of Use
Emend has not been studied for the treatment of established nausea and vomiting.
Chronic continuous administration is not recommended because it has not been studied and because the drug interaction profile may change during chronic continuous use.

Emend (fosaprepitant dimeglumine) for injection
Emend for Injection is a substance P/neurokinin-1 (NK1) receptor antagonist indicated in adults for use in combination with other antiemetic agents for the:
• prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
• prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use
Emend for Injection has not been studied for the treatment of established nausea and vomiting.
Chronic continuous administration is not recommended

COVERAGE CRITERIA

Emend will be covered with prior authorization when the following criteria are met:
• Patient is NOT currently taking pimozide (Orap)
AND
• Emend is being prescribed for the prevention of postoperative nausea and vomiting
OR
• Emend is being prescribed for the prevention of nausea and vomiting associated with highly or moderately emetogenic chemotherapy AND will be used in combination with other antiemetic agents

Quantity Limits apply.
**POST LIMIT QUANTITY**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Quantities to approve</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emend 80 mg Capsules</td>
<td>16 capsules / 21 days</td>
</tr>
<tr>
<td>Emend 125 mg Capsules</td>
<td>4 capsules / 21 days</td>
</tr>
<tr>
<td>Emend Tri-pack (contains one 125mg and two 80mg)</td>
<td>4 packs / 21 days</td>
</tr>
<tr>
<td>Emend 125 mg for Oral Suspension (Single-Dose Kit)</td>
<td>12 kits / 21 days</td>
</tr>
<tr>
<td>Emend 150 mg Injection</td>
<td>4 vials / 21 days</td>
</tr>
<tr>
<td>Emend 40 mg capsule</td>
<td>6 capsules / 6 months</td>
</tr>
</tbody>
</table>

*This drug is indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit. The duration of 21 days is used for a 28-day fill period.*

**REFERENCES**